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Purpose: To evaluate the diode laser photodynamic therapy efficacy on choroidal neovascularization (CNV) 
in the treatment of three patients with age-related macular degeneration (ARMD).
Methods:  The authors selected three patients with ARMD whose vision has decreased due to CNV, and 
applied diode laser treatment after injecting an indocyanine green (ICG) solution. The patients were followed 
for at least three months after treatment, and examinations included evaluating vision changes and possible 
leakage on fluorescein angiography (FAG).
Results: The final vision of two patients improved by more than one line on the Early Treatment Diabetic 
Retinopathy Study (ETDRS) chart after at least three months of follow-up. However, the final vision of the 
third patient decreased by one line on ETDRS chart. FAG was done in all patients, and in two of the 
patients, there was no evidence of leakage at the laser-applied site. In the other patient, there was evidence 
of minimal leakage, with the area of leakage decreasing by more than fifty percent. Side effects of ICG were 
not found during or after the photodynamic therapy sessions.
Conclusions: The photodynamic usage of ICG treatment of CNV in patients with ARMD, was effective in 
preventing or improving the visual outcome. Compared to the widely used verteporfin, ICG is more stable 
and is more cost effective. The authors therefore came to a conclusion that ICG can be very useful in the 
treatment of CNV. However, further studies are necessary.  
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Choroidal neovascularization (CNV) arises underneath the 
retinal pigment epithelial (RPE) layer, and is characterized by 
hemorrhage, retinal edema, subretinal edema, fibrosis, and 
eventually loss of vision. Among various causes of CNV, 
age-related macular degeneration (ARMD) is an important 
cause of blindness in the elderly population in the Western 
hemisphere. The incidence of ARMD is also increasing in 
Korea, due tothe growing elderly population. 
Laser photocoagulation has been recommended as a 
conventional treatment modality. However, in cases with 
subfoveal CNV, foveal damage during photocoagulation was 
inevitable, causing decrease in vision, central scotoma, and 
a high incidence of recurrence. Compared to conventional 
photocoagulation, photodynamic therapy (PDT) with verte-
porfin was able to induce regression of neovascularization 
while minimizing the retinal damage.  
However, one of the side-effects of verteporfin is photo-
sensitivity, and when patients were exposed to light after the 
photodynamic therapy with verteporfin, they complained of 
skin rashes or pruritis. The patients were unable to go outside 
for 48 hours after receiving PDT with verteporfin. Furthe-
rmore, when there is a leakage of the dye during the 
injection, the patient may develop skin necrosis, and rarely, 
the patient may experience back pain. Due to the treatment’s 
high cost, many patients have given up on the treatment 
altogether.
In contrast, the indocyanine green (ICG) dye is very stable, 
has no photosensitivity, is inexpensive, and has been used in 
the fluorescein angiography for years. Because there have 
been reports of the effective outcome of treating CNV 
patients with ICG dye, the authors selected three CNV 
patients with ARMD and treated these patients by photo-
dynamic therapy with ICG dye. The authors then analyzed 
the clinical results of these patients, examining the photo-
dynamic effectiveness of ICG dye (and its superiority to 
verteporfin in stability and cost) in the treatment of CNV in 
patients with ARMD.Kor J Ophthalmol Vol.21, No.1, 2007
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Fig. 1. Color photograph and angiographic findings of CNV due
to ARMD. (A) The color photograph shows RPE atrophy and 
hypertrophy in the macular area of the left eye. (B) Early phase
of FAG before treatment shows classic CNV in the subfoveal 
area, which is smaller than one disc diameter. (C) Late phase of
FAG before treatment shows hyperfluorescence from leakage on
CNV area. (D) Three months after treatment, no leakage was 
noted on FAG or hyperfluorescence due to RPE atrophy.
Case Report
Among the patients who were diagnosed with CNV due 
to ARMD and underwent PDT from April of 2003 to the 
present, the authors selected three patients (three eyes total) 
for retrospective analysis. With each patient, visual acuity 
with and without correction was measured, and the anterior 
segment of the patients’ eyes were examined with a slit-lamp. 
A dilated retinal exam was also done with contact lenses and 
an indirect ophthalmoscope, and FAG was done in order 
to identify CNV. The patients were asked about allergic 
reactions to iodine, shellfish, and crustaceans, all of which 
were negative.
PDT was conducted by intravenously injecting ICG dye 
with concentration of 50 mg/2.5 cc (Diagnogree, Cheil 
pharmaceutical co., Japan). In order to allow the dye to reach 
the eye without dilution, 5 cc of normal saline was injected. 
Then, the diode laser with a wavelength of 805 nm was 
mounted on the slit-lamp and applied to the retina with the 
spot size of 3000 µm for 90 seconds. The authors calibrated 
the power of the laser between 575 mW and 1500 mW. The 
patients were then followed-up for one month after the PDT, 
and then three months after that.
Afterwards, the authors examined the patients once every 
three months and measured the best-corrected visual acuity 
with the ETDRS chart, conducted a dilated retinal exami-
nation, and performed FAG. With the natural progression of 
CNV in mind, the authors defined stabilization of visual 
acuity after PDT as the visual acuity decreasing by less than 
two lines on ETDRS chart. The authors defined progress of 
visual acuity as the patient obtaining more than one line of 
improvement on ETDRS chart.
When there was no leakage compared to the previous 
findings identified by FAG, the patient was said to have “no 
leakage”. The patient was said to have “minimal leakage” 
when the area of leakage was no more than fifty percent of 
the original leakage, and “moderate leakage” when the area 
was more than fifty percent. Finally, when the leakage 
exceeded the original area of the lesion, the progression” 
label was given to the patient’s leakage, and the analysis was 
completed.
Case 1
A 74-year-old male patient reported a decrease in visual 
acuity in his left eye that began six months before his initial 
visit to the hospital. His vision with or without correction on 
his left eye was 20/2000, and his vision with and without 
correction on his right eye was 20/25 and 20/50, respectively.
The patient had no past history of hypertension or diabetes, 
and the anterior segment of his eye appeared normal. Dilated 
retinal examination showed atrophy as well as hypertrophy 
of the retinal pigment epithelial (RPE) layer in the left foveal 
region. The patient also had an exudate. FAG showed classic 
CNV the size of an optic disc, located in the subfoveal 
region. The lesion showed hyperfluorescence at first; the area 
of hyperfluorescence increased towards the end of the FAG 
due to leakage (Fig. 1A-C).
ICG dye was injected intravenously with a concentration 
of 50 mg/2.5 cc. Two minutes later, an additional 5 cc of 
normal saline was injected. The diode laser was then applied 
to the patient’s retina with the spot size of 3000 µm for 90 
seconds. The authors calibrated the power of laser at 1000 
mW. There were no allergic or adverse effects due to ICG 
dye during or after the therapy session.
The patient was followed-up for three months, and his 
best-corrected visual acuity one month after the treatment 
increased by one line to 20/800. However, his visual acuity 
showed no additional improvement three months after the 
treatment. The authors looked at his FAG taken three months 
after the treatment, and found “no leakage” on both occasions 
(Fig. 1D).
During his final visit, the authors found atrophy of the 
retinal pigment epithelial layer, and there was no evidence of 
RPE detachment. However, the patient continued to complain 
of metamorphopsia.
Case 2
A 66-year-old female patient complained of metamor-
phopsia beginning three months before her initial visit to the 
hospital. Her visual acuity with or without correction was CK Yoon, et al. INDOCYANINE PHOTODYNAMIC THERAPY
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Fig. 2. Color photograph and angiographic findings of CNV due
to ARMD. (A) The color photograph shows RPE atrophy and 
hypertrophy, soft drusen, and exdudate in the macular area of 
the right eye. (B) Early phase of FAG before treatment shows 
occult CNV in the subfoveal area, which is smaller than one disc
diameter. (C) Late phase of FAG before treatment shows 
hyperfluorescence from leakage in the CNV-involved area. (D) 
Nine months after treatment, minimal leakage was noted on FAG.
Fig. 3. Color photograph and angiographic findings of CNV due
to ARMD. (A) The color photograph shows RPE atrophy and 
hypertrophy, soft drusen, and exdudate in the macular area of 
the right eye. A small amount of hemorrhage is also observed 
around the macular area. (B) Early phase of FAG before 
treatment shows a hyperfluorescent lesion on the nasal side of 
the macula due to RPE atrophy. (C) Late phase of FAG before
treatment shows hyperfluorescence from leakage of occult CNV
in the subfoveal area, which is smaller than one disc diameter.
(D) Nine months after treatment, no leakage was noted on FAG.
20/400 in her right eye and 20/25 in her left eye. The patient 
had no past history of hypertension or diabetes, and the 
anterior segment of her eyes appeared normal.
Dilated retinal examination showed atrophy as well as 
hypertrophy of right foveal region, and the patient also had 
a soft drusen and exudate. The patient’s FAG showed occult 
CNV the size of an optic disc located in the subfoveal region, 
and an area of hyperfluorescence increased towards the end 
of the FAG due to leakage (Fig. 2A-C).
ICG dye was injected intravenously, and a diode laser was 
applied to the patient’s retina with the spot size of 3000 µm 
for 90 seconds. The authors calibrated the power of the laser 
at 1500 mW.
The patient was followed up for nine months, and her 
best-corrected visual acuity improved by more than two lines 
to 20/250. The degree of metamorphopsia also decreased. 
According to FAG taken nine months after the treatment, the 
patient showed “minimal leakage”, involving an area no more 
than 50% of the original leakage (Fig. 2D). Dilated retinal 
examination done in her final visit showed atrophic changes 
in the retinal epithelial layer, and there was no evidence of 
retinal hemorrhage or RPE detachment. 
The patient did not experience any allergic or adverse 
reactions to the ICG dye during or after the treatment session.
Case 3
A 56-year-old male patient reported decreased visual 
acuity and metamorphopsia beginning six months prior to the 
initial visit to the hospital. His visual acuity with or without 
correction was 20/2000 in his right eye, and 20/25 in his left 
eye. The patient had no past history of hypertension or 
diabetes, and the anterior segment of his eyes appeared 
normal.
Dilated retinal examination showed atrophy as well as 
hypertrophy of the retinal epithelial layer in his right macular 
region. There was no evidence of a soft drusen or small areas 
of retinal hemorrhage in the macula. FAG revealed a 
hyperfluorescent area located in the nasal macular region due 
to atrophy of the RPE layer, and a subfoveal occult CNV the 
size of an optic disc showed increase in the area of 
hyperfluorescence towards the end of the FAG due to leakage 
(Fig. 3A-C).
ICG dye with a concentration of 50 mg/5 cc was injected 
intravenously, and a diode laser was applied to the patient’s 
retina with the spot size of 3000 µm for 90 seconds. The 
power of laser was calibrated at 575 mW.
The patient was then followed up for nine months, and his 
final best-corrected visual acuity of the right eye worsened 
by one line on the chart at 20/1333. Metamorphopsia also 
remained. His final FAG findings showed “no leakage” (Fig. 
3D). Dilated retinal examination done in his final visit Kor J Ophthalmol Vol.21, No.1, 2007
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revealed atrophy of the RPE layer, and there was no evidence 
of retinal hemorrhage or RPE detachment.
The patient also reported no allergic or adverse reactions 
to ICG dye during or after the treatment session.
Discussion
CNV occurs underneath the retina or RPE layer, and 
leakage or hemorrhage because of neovascularization, 
ischemia, or fibrosis can damage the retina, decreasing visual 
acuity.
1,2
Causative factors of CNV include ARMD, ocular histo-
plasmosis, high myopia, and other idiopathic causes.
3  Among 
these causes, ARMD is a degenerative disease of the macula 
which occurs in patients in their fifties and older. It is 
characterized by soft drusen, hyper- or hypopigmentation of 
the RPE layer, detachment of the sensory retina, retinal 
hemorrhage, geographic atrophy of the RPE, and CNV or 
fibrotic changes of the retina. In the Western hemisphere, 
ARMD has become a main cause of blindness in the elderly 
population over 60 years of age. Its prevalence is also increasing 
in Korea.
4 It can be classified into atrophic or exudative 
degeneration, and most cases of severe visual loss occur in 
patients with exudative ARMD with accompanying CNV.
Many different treatment modalities have been tried in 
order to cure CNV, including pharmaceutical or radiological 
therapy, subfoveal surgery, or laser photocoagulation.
5 
Different pharmaceutical treatments have also been tried 
(e.g., thalidomide, interferon α-2a, and anti-VEGF) but 
they were generally ineffective; research is still ongoing.
6 
Radiological therapy was known to reduce proliferation of 
vascular endothelial cells ex vivo, thereby preventing 
proliferation of neovascular vessels in vivo. However, 
there have been contrasting reports regarding maintenance 
or amelioration of visual acuity after treatment.
7  Subfoveal 
surgery has been tried in patients who have severe subfoveal 
hemorrhage and CNV, in patients with large CNV where 
laser photocoagulation cannot be done, and in patients with 
CNV which has ambiguous margin. However, there have 
been reports of serious complications such as the develop-
ment of cataract, the recurrence of CNV, and retinal detach-
ment. Finally, laser photocoagulation can decrease the in-
cidence of severe visual loss, but in cases of subfoveal CNV, 
hyperthermia caused by laser can also damage healthy 
sensory retina. Cases are limited where laser treatment can 
be effective, and recurrence after five years is more than 
50%.
8  Thus, in patients with subfoveal CNV, there are no 
satisfactory treatments.
However, while studying agents that can selectively work 
with CNV, PDT (which employs photosensitive agents) 
has been developed. PDT has been clinically proven in the 
treatment against cancer, and research has been conducted in 
order to prove its efficacy in the treatment against CNV. 
Schmidt-Erfurth and Hasan reported that photosensitive 
agents can be absorbed into neovascular vessels, and they 
successfully demonstrated photothrombosis in an experiment 
involving animals.
9 Among photosensitive agents, the second- 
generation agent verteporfin has been proven to selectively 
induce CNV regression, and because the agent can also 
prevent laser-induced hyperthermia, it has become a widely 
used agent during photodynamic therapy.
10,11
Verteporfin can bind with tumors that have multiple low- 
density lipoprotein (LDL) receptors and can also selectively 
unite with neovascular vessels, thereby giving out singlet 
oxygen and free radical. As a result, new vessels may 
become clogged due to photothrombosis.
12 PDT, which 
employs verteporfin, has been proven in the treatment of 
CNV due to ARMD after a random prospective study of the 
treatment of AMD with photodynamic therapy (TAP) was 
published, and this study included two years of clinical 
results.
13 In the phase I and II study that examined the safety 
of verteporfin, short-term visual outcome and effectiveness 
was exemplified by FAG: hyperfluorescent leakage decrease-
dafter a short period of time (one to four weeks), and normal 
retinal vessels or visual acuity remained intact. The study 
also showed that the leakage coming out of CNV recurred 
after 12 weeks.
14,15
However, after injecting verteporfin, patients reported 
photosensitive symptoms such as rash, eczema, facial edema 
and flushing. The patients were instructed not to expose their 
skin, eyes, or other organs directly to sunlight, artificial 
tanning machines, bright halogen light, or other sources of 
bright indoor lighting. Furthermore, when verteporfin is 
injected along with other photosensitizing agents such as 
tetracycline, sulfonamides, phenothiazines, sulfonylurea, 
hypoglycemic agents, thiazide diuretics, and griseofulvin, a 
photo-allergic reaction may be amplified. Additionally, when 
verteporfin is used with free radical oxygen, anticoagulants, 
agents which constrict vessels, thromboxane A2, dimethyl 
sulfoxide, betacarotene, ethanol, formate, or mannitol, its 
therapeutic effect decreased markedly. When the patient is 
taking calcium channel blockers or polymyxin-B or is 
receiving ultraviolet therapy, the therapeutic effects of 
verteporfin will also decrease because these agents decrease 
selectivity to neovasculature. In order to overcome these 
defects of verteporfin, some studies started to employ ICG 
dye in PDT because the dye does not cause photo-
sensitivity.
16
ICG is an anionic tricarbocyanine lavender-hued dye, and, 
ever since it was introduced by an American Fox in 1957, 
it has been widely used in liver and heart function tests. It 
has also been used in FAG of the retina and choroid for more 
than thirty years.
17 After the dye is injected intravenously, it 
combines with blood proteins and spreads throughout the 
body. Because it is absorbed by the liver, it does not pass 
freely through the gastrointestinal tract or through the 
kidneys. Twenty minutes after injection, 97% of the dye is 
digested by the liver and excreted through the gallbladder. 
This makes the dye a very stable agent when measuring liver 
and circulatory function, because one can freely determine CK Yoon, et al. INDOCYANINE PHOTODYNAMIC THERAPY
59
the residual amount in the blood or its loss thereof, and the 
amount of blood flow into the liver. With the exception of 
patients who are allergic to iodine (which is included in the 
ICG), the dye is safe to use, and it poses no toxicity to skin.
When ICG is diluted into a solution, its maximum 
wavelength changes from 780 nm to 805 nm after it 
combines with blood proteins, and such a property can be 
used in PDT. PDT consists of two parts: the injection of a 
photosensitive agent and the application of a non-thermal 
laser to the sensitized tissue. After the injection of ICG, the 
dye unites with blood proteins (e.g. LDL, albumin, etc.) and 
among these proteins, LDL increases in number within 
vascular endothelial cells of rapidly proliferating cells (such 
as choroidal neovascular vessels). The expression of LDL 
receptor also increases accordingly. Thus, the combined unit 
of ICG and LDL accumulates within CNV, and when the 
non-thermal laser is applied to the site, this unit changes from 
a ground singlet form to an excited triplet form. ICG makes 
a photochemical reaction with this triplet form, giving rise to 
free radicals or transforming it into singlet oxygen. These 
singlet oxygen and free radicals can damage the endothelial 
cells, expose the basement membrane of vessels, and activate 
the platelets, thereby making the platelets combine and 
coagulate. These activated platelets can secrete vasoactive 
mediators, causing thrombosis and constriction of vessels, 
thereby clogging the new vessels.
Among non-thermal lasers employed in the PDT, the ICG 
enhanced diode laser photocoagulation was first used by 
Puliafito et al. for the treatment of CNV.
18 The wavelength 
of the diode laser varies between 780 and 840 nm, and the 
laser has maximum output of 2~3 W, making photoco-
agulation of retina possible. Also, maximum absorption wave-
length of ICG dye is identical to that of the laser at 805 nm, 
enabling the laser to penetrate deep into the tissue.
19 
Furthermore, the wavelength is within that of the infra-red 
light, making penetration through cornea and lens easy, and 
since the laser is not absorbed by other pigments such as 
xanthophylls, flavoprotein, and glutathion peroxidase, it can 
be very useful in the treatment of subfoveal lesions.
20
In one study published Obana et al., which examined the 
effectiveness of ICG dye and diode laser, Obana reported the 
therapeutic effect in regression of macular CNV to be up 
to 92%.
21
While Obana conducted his clinical study with humans, 
the authors of this study previously took pigmented rats, and, 
after creating artificial CNV in the retina of rats, injected 
ICG dye, applied a diode laser, and observed the regression 
of CNV. The authors found that the therapeutic effect of such 
treatment to be up to 85%.
22
When the authors analyzed the clinical results of this 
study, one month after the treatment, there was visual 
improvement of 0.3 lines. Three months after the treatment, 
there was another 0.3 lines of improvement. The visual acuity 
did not continue to improve six months and nine months after 
the treatment, and the overall average increase in visual 
acuity was 0.2 lines. As FAG data were analyzed, two eyes 
had “no leakage” while one eye had “minimal leakage.
In the TAP study that studied the effectiveness of PDT 
with verteporfin, improvement of visual acuity was defined 
as improving more than a line on ETDRS chart after taking 
into account the natural progression of CNV. One can argue 
that the authors’ study failed to prove that the therapy with 
ICG failed to bring about improvements in visual acuity. 
However, the visual acuity can be defined as stable when 
there is deterioration of no more than two lines on the chart, 
and the authors concluded that the therapy with ICG at least 
can stabilize the progression of CNV. Also, when the authors 
looked at the changes in the amount of leakage on FAG, 
“moderate leakage” (greater than 50% of the original 
leakage) or “progression” did not occur in all patients, further 
exemplifying the CNV-stabilizing effect of PDT with ICG. 
The location of CNV in all three cases was either directly 
subfoveal or near the area, and because there was no massive 
hemorrhage, the final visual outcome of PDT could have 
been good.
This study does have its limitations that, unlike the TAP 
study that studied the effectiveness of PDT with verteporfin, 
the authors did not attempt to treat the patient when there 
was further leakage on FAG, and the patient pool was rather 
small. Also, in one patient’s eye, only a short period of 
follow-up (three months) was possible, making a direct 
comparison of ICG to verteporfin difficult.
However, compared to the TAP study, the visual acuity 
stabilizing effect of ICG was comparable to that of 
verteporfin, making the dye useful in the treatment of ARMD 
with CNV. Furthermore, compared to verteporfin, ICG is 
safer because it does not give rise to any allergic or adverse 
reactions to light, and is cost effective. 
Thus, the authors concluded that in patients with decreased 
visual acuity due to ARMD with concomitant CNV, PDT 
with ICG can be employed with expectation of improving the 
visual acuity at a relatively cheaper cost. 
Further studies are necessary in order to compare both the 
short- and long-term visual outcomes of PDT with ICG dye, 
and also to study whether such treatment can be employed 
with other causes of CNV such as pathologic myopia, ocular 
histoplasmosis, and idiopathic CNV.
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